Sanosil Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 03-07-2024
- Paid Up Capital ₹ 1.00 M
as on 03-07-2024
- Company Age 37 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.00 Cr
as on 03-07-2024
- Revenue -19.45%
(FY 2023)
- Profit -242.44%
(FY 2023)
- Ebitda -117.01%
(FY 2023)
- Net Worth -5.92%
(FY 2023)
- Total Assets 48.20%
(FY 2023)
About Sanosil Biotech
The Corporate was formerly known as Sanosil Chemicals (India) Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹11.00 Cr.
Sureshkumar Eranghikalam and Dev Gupta serve as directors at the Company.
- CIN/LLPIN
U24110MH1987PTC043157
- Company No.
043157
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Apr 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sanosil Biotech Private Limited offer?
Sanosil Biotech Private Limited offers a wide range of products and services, including Insecticides and Pesticides, Fungicides, Disinfection Equipment & Machines, Fumigation Machine.
Who are the key members and board of directors at Sanosil Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dev Gupta  | Director | 29-Sep-2004 | Current |
| Sureshkumar Eranghikalam | Director | 01-Sep-2014 | Current |
Financial Performance of Sanosil Biotech.
Sanosil Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.45% decrease. The company also saw a substantial fall in profitability, with a 242.44% decrease in profit. The company's net worth dipped by a decrease of 5.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanosil Biotech?
In 2023, Sanosil Biotech had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Mar 2019 | ₹11.00 Cr | Open |
How Many Employees Work at Sanosil Biotech?
Sanosil Biotech has a workforce of 21 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanosil Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanosil Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
